Commercial sensitivity or patient protection? Secrecy and medicine safety

Description

Researchers have identified an information gap between pharmacological companies and Australian clinicians on the potential safety risks of medicines.

Subject

Medication safety alerts from post-marketing surveillance varies from country to country. There is a failure to make these alerts public and there is a failure of governance at a national level.